Lentiviral Transfer Vector Layout for Faster RNA Export and Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lentiviral vectors exhibit low gene expression levels, are inefficient, laborious, and costly, posing biosafety and toxicity concerns, and require slow and cumbersome viral production processes.
Innovation Solution
Development of optimized lentiviral transfer vectors with specific features such as a CMV promoter, mutated INS1 inhibitory sequence, absence of INS2, INS3, and INS4 sequences, and inclusion of elements like psi, rev-response element, and post-transcriptional regulatory elements, which enhance gene expression and production efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing lentiviral vectors are used, then viral particles can be produced to infect target cells, but gene expression levels are low and production is slow and inefficient
Solution Approach 1:
The patent modifies specific parameters of the lentiviral vector sequence, including mutations in the INS1 inhibitory sequence (changing specific nucleotides to reduce restriction of nuclear export), removal of INS2/INS3/INS4 sequences, and optimization of the gag protein coding sequence. These parameter changes result in enhanced viral production efficiency and reduced production time while maintaining biosafety.
Solution Approach 2:
The patent extracts and removes harmful or restrictive elements from the viral vector, specifically deleting the INS2, INS3, and INS4 inhibitory sequences that were present in wild-type lentiviral vectors. This extraction eliminates the restrictive effects on nuclear export and improves production efficiency without compromising safety.
2Reliability
If existing lentiviral vectors are used, then viral particles can be produced, but biosafety and toxicity concerns arise
Solution Approach 1:
The patent converts potentially harmful wild-type sequences into beneficial modified sequences by introducing mutations in the INS1 region that reduce restrictive effects while maintaining safety. The removal of INS2/INS3/INS4 sequences eliminates harmful restrictive functions, transforming them into beneficial conditions that enhance production while preserving biosafety through controlled vector design.
3Productivity
If existing lentiviral vectors are used, then heterologous gene expression can be induced, but the process is laborious and expensive
Solution Approach 1:
The patent segments the viral vector into optimized functional components with specific mutations in key regions (INS1, INS2, INS3, INS4), allowing each component to perform its function efficiently. This segmentation enables streamlined production processes and reduces manufacturing complexity while maintaining high gene expression induction capability.
Data Source
AI summary
The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.